THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

Male health supplements have become increasingly important in today's fast-paced world where nutritional gas and lifestyle ...

Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the ...

The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It includes biological and m ...

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License ...

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial. Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025. SEATTLE and VANCOUVER, British C ...

Incyte (Nasdaq:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided full year 2025 financial guidance. "2024 ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...

KalVista Pharmaceuticals, Inc. , today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...